CL2016000263A1 - Compuestos terapéuticamente activos y sus métodos de uso. - Google Patents

Compuestos terapéuticamente activos y sus métodos de uso.

Info

Publication number
CL2016000263A1
CL2016000263A1 CL2016000263A CL2016000263A CL2016000263A1 CL 2016000263 A1 CL2016000263 A1 CL 2016000263A1 CL 2016000263 A CL2016000263 A CL 2016000263A CL 2016000263 A CL2016000263 A CL 2016000263A CL 2016000263 A1 CL2016000263 A1 CL 2016000263A1
Authority
CL
Chile
Prior art keywords
methods
active compounds
therapeutically active
leukemia
myelocitic
Prior art date
Application number
CL2016000263A
Other languages
English (en)
Inventor
Samuel V Agresta
David Schenkein
Hua Yang
Liting Guao
Zhen Tang
Jianming Wang
Yanfeng Zhang
Yan Zhou
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2016000263A1 publication Critical patent/CL2016000263A1/es
Priority to CL2017002240A priority Critical patent/CL2017002240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMA CRISTALINA AISLADA DE COMPUESTOS 1,3,5-TRIAZIN SUSTITUIDOS, INHIBIDORES DE IDH2; Y METODO PARA TRATAR UNA NEOPLASIA HEMATOLOGICA AVANZADA SELECCIONADA DE LEUCEMIA MIELOGENA AGUDA, SINDROME MIELODISPLASICO, LEUCEMIA MIELOCITICA CRONICA, SARCOMA MIELOIDE, MIELOMA MULTIPLE Y LINFOMA, DEFINIDAS POR UN ALELO MUTANTE DE IDH2.
CL2016000263A 2013-08-02 2016-02-02 Compuestos terapéuticamente activos y sus métodos de uso. CL2016000263A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2017002240A CL2017002240A1 (es) 2013-08-02 2017-09-04 Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
US201461939098P 2014-02-12 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US201462011948P 2014-06-13 2014-06-13
PCT/US2014/049469 WO2015017821A2 (en) 2013-08-02 2014-08-01 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
CL2016000263A1 true CL2016000263A1 (es) 2016-08-19

Family

ID=52432592

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000263A CL2016000263A1 (es) 2013-08-02 2016-02-02 Compuestos terapéuticamente activos y sus métodos de uso.
CL2017002240A CL2017002240A1 (es) 2013-08-02 2017-09-04 Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002240A CL2017002240A1 (es) 2013-08-02 2017-09-04 Formas cristalinas del compuesto 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol metanosulfonato; composición farmacéutica; usos en el tratamiento de neoplasias hematológicas avanzadas (divisional solicitud 263-2016).

Country Status (21)

Country Link
US (5) US9738625B2 (es)
EP (3) EP3027193A4 (es)
JP (3) JP6742905B2 (es)
CN (3) CN110372670B (es)
AU (2) AU2014295938B2 (es)
BR (1) BR112016002287A2 (es)
CA (1) CA2919382A1 (es)
CL (2) CL2016000263A1 (es)
EA (1) EA030428B1 (es)
ES (1) ES2886211T3 (es)
IL (2) IL243833A0 (es)
MX (2) MX2020011397A (es)
MY (1) MY177994A (es)
NI (1) NI201600022A (es)
PE (1) PE20160840A1 (es)
PH (1) PH12016500164A1 (es)
SA (1) SA516370523B1 (es)
SG (2) SG11201600479WA (es)
TW (2) TWI666208B (es)
UA (1) UA121021C2 (es)
WO (1) WO2015017821A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002287A2 (pt) * 2013-08-02 2017-08-01 Agios Pharmaceuticals Inc compostos terapeuticamente ativos e seus métodos de uso
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10201543B2 (en) 2015-02-04 2019-02-12 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
ES2881695T3 (es) 2015-07-30 2021-11-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de 1,3,5-triazina y método de uso del mismo
JP6816106B2 (ja) 2015-08-05 2021-01-20 アジオス ファーマシューティカルズ， インコーポレイテッド ６−ピリジル−１，３，５−トリアジン−２，４−ジオール及び６−ピリジル−１，３，５−トリアジン−２，４−ジアミンを調製する方法
EP3362070B1 (en) * 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
MA43848A (fr) * 2015-10-21 2018-11-21 Neuform Pharmaceuticals Inc Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
CA3007218A1 (en) * 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
MX2018010261A (es) 2016-02-26 2019-02-11 Agios Pharmaceuticals Inc Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
US20180042930A1 (en) 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
WO2018048847A1 (en) * 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
ES2924500T3 (es) 2017-01-22 2022-10-07 Chia Tai Tianqing Pharmaceutical Group Co Ltd Sal de derivado de 1,3,5-triazina, cristal, método de preparación, composición farmacéutica y uso de la misma
US11229653B2 (en) 2017-05-05 2022-01-25 Celgene Corporation Methods of treatment of myeloproliferative neoplasm
SG11201913008TA (en) 2017-06-30 2020-01-30 Celgene Corp Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20210403452A1 (en) * 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
EP0466647B1 (de) 1990-07-12 1995-11-29 Ciba-Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
AU5379900A (en) 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP2256108B1 (en) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
US8258295B2 (en) * 2007-04-30 2012-09-04 Prometic Biosciences Inc. Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
BRPI1010881A2 (pt) * 2009-06-08 2016-05-31 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
AR080945A1 (es) * 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
WO2013102431A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
BR112016000489A8 (pt) 2013-07-11 2020-01-07 Agios Pharmaceuticals Inc composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112016002287A2 (pt) * 2013-08-02 2017-08-01 Agios Pharmaceuticals Inc compostos terapeuticamente ativos e seus métodos de uso
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10201543B2 (en) 2015-02-04 2019-02-12 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
SA516370523B1 (ar) 2019-01-10
EP3566706B1 (en) 2021-07-14
EP3566706A1 (en) 2019-11-13
US20170305885A1 (en) 2017-10-26
JP2019142930A (ja) 2019-08-29
NZ716226A (en) 2021-08-27
EA030428B1 (ru) 2018-08-31
US10730854B2 (en) 2020-08-04
US20240132474A1 (en) 2024-04-25
US10093654B2 (en) 2018-10-09
CN110372670B (zh) 2023-04-07
SG11201600479WA (en) 2016-02-26
US9738625B2 (en) 2017-08-22
CA2919382A1 (en) 2015-02-05
JP2016527279A (ja) 2016-09-08
EP3932408A1 (en) 2022-01-05
CN105916507A (zh) 2016-08-31
PE20160840A1 (es) 2016-09-22
MX2016001361A (es) 2016-06-14
MX2020011397A (es) 2022-08-05
EP3027193A2 (en) 2016-06-08
TWI666208B (zh) 2019-07-21
CL2017002240A1 (es) 2018-04-20
AU2014295938B2 (en) 2018-07-19
TWI701242B (zh) 2020-08-11
JP2021176893A (ja) 2021-11-11
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
SG10201709187TA (en) 2017-12-28
EP3027193A4 (en) 2017-04-26
PH12016500164A1 (en) 2016-04-25
IL270347B (en) 2021-08-31
AU2018247242B2 (en) 2020-03-12
AU2018247242A1 (en) 2018-11-01
US20210155603A1 (en) 2021-05-27
IL243833A0 (en) 2016-04-21
ES2886211T3 (es) 2021-12-16
JP6742905B2 (ja) 2020-08-19
BR112016002287A2 (pt) 2017-08-01
EA201690322A1 (ru) 2016-07-29
AU2014295938A1 (en) 2016-02-18
CN110386922A (zh) 2019-10-29
WO2015017821A3 (en) 2015-04-09
US20180370951A1 (en) 2018-12-27
NI201600022A (es) 2016-03-16
TW201932455A (zh) 2019-08-16
CN110372670A (zh) 2019-10-25
US20160194305A1 (en) 2016-07-07
TW201524971A (zh) 2015-07-01
UA121021C2 (uk) 2020-03-25

Similar Documents

Publication Publication Date Title
CL2016000263A1 (es) Compuestos terapéuticamente activos y sus métodos de uso.
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
PH12018500342A1 (en) Heterocyclic amides as kinase inhibitors
DOP2017000150A (es) Anticuerpos anti-cd 38 para el tratamiento de leucemia mieloides aguda
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
EA201891211A1 (ru) Ингибиторы cxcr2
PE20181323A1 (es) Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
ECSP17054980A (es) Inhibidores selectivos de bace1
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
UY34559A (es) Inhibidores de bromodominios
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
UY34156A (es) Compuestos inhibidores de metaloenzimas
EA201500947A1 (ru) Устройство и способ электроосаждения нанослоистого покрытия
BR112015024558A2 (pt) método para tratamento de leucemia mieloide.
NZ738087A (en) Directed energy deposition to facilitate high speed applications
NZ711192A (en) Process for making benzoxazepin compounds
EP2981507A4 (en) Metal compound, method for preparing the same, selective metallization of surface of substrate with the metal compound
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
EP3009131A4 (en) Agents for treating multiple myeloma
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2016016127A (es) Formas cristalinas.
MX2020006006A (es) Polimorfos cristalinos de {(2s,3r)-1-[(2s)-2-{5-[(2r,5r)-1-{3,5-di fluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}-5-(6-fluoro-2-{( 2s)-1-[n-(metoxicarbonil)-o-metil-l-treonil]pirrolidin-2-il}-1h-b enzimidazol-5-il)pirrolidin-2-il]-6-fluoro-1h-benzimidazol-2-il}p irrolidin-1-il]-3-metoxi-1-oxobutan-2-il}carbamato de metilo.
DK201300179U1 (da) Kemisk forbindelse med nyttige egenskaber